Rare COVID Vaccine Clotting Linked to Adenoviral Protein - Takeaways - MDSpire
From the Journals

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 12, 2026

  • 3 min

Share

  • 1

    VITT is a rare clotting disorder linked to adenovirus vaccines.

  • 2

    Immune response targets PF4, a normal clotting protein.

  • 3

    Study employed antibody proteomics and mass spectrometry.

  • 4

    Adenoviral core protein VII identified as triggering antigen.

  • 5

    Patients shared a specific immunoglobulin light-chain variant.

  • 6

    Modifying pVII could enhance vaccine safety.

  • 7

    Research findings aim to prevent rare adverse reactions while maintaining efficacy.

Original Source(s)

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

  • May 12, 2026

Related Content

Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...